GB0319227D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0319227D0
GB0319227D0 GB0319227A GB0319227A GB0319227D0 GB 0319227 D0 GB0319227 D0 GB 0319227D0 GB 0319227 A GB0319227 A GB 0319227A GB 0319227 A GB0319227 A GB 0319227A GB 0319227 D0 GB0319227 D0 GB 0319227D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0319227A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GBGB0305929.2A priority Critical patent/GB0305929D0/en
Application filed by Novartis AG filed Critical Novartis AG
Priority to GB0319227A priority patent/GB0319227D0/en
Publication of GB0319227D0 publication Critical patent/GB0319227D0/en
Priority to ES10009414T priority patent/ES2409885T3/en
Priority to EP10009414A priority patent/EP2275413B1/en
Priority to BR122019010008A priority patent/BR122019010008B8/en
Priority to AT04719989T priority patent/ATE497495T1/en
Priority to KR1020057017082A priority patent/KR101148261B1/en
Priority to SI200432034T priority patent/SI2275413T1/en
Priority to MXPA05009883A priority patent/MXPA05009883A/en
Priority to EP04719989A priority patent/EP1606265B1/en
Priority to PL10009414T priority patent/PL2275413T3/en
Priority to NZ542219A priority patent/NZ542219A/en
Priority to PCT/EP2004/002616 priority patent/WO2004080980A1/en
Priority to PT04719989T priority patent/PT1606265E/en
Priority to CA2518932A priority patent/CA2518932C/en
Priority to DK10009414.3T priority patent/DK2275413T3/en
Priority to CN2004800130419A priority patent/CN1788001B/en
Priority to PL04719989T priority patent/PL1606265T3/en
Priority to AU2004220338A priority patent/AU2004220338B2/en
Priority to RU2005131721/04A priority patent/RU2400477C2/en
Priority to DE602004031287T priority patent/DE602004031287D1/en
Priority to PT100094143T priority patent/PT2275413E/en
Priority to BRPI0408347A priority patent/BRPI0408347B8/en
Priority to US10/549,250 priority patent/US7964592B2/en
Priority to JP2006504673A priority patent/JP4796487B2/en
Priority to CN2010102347117A priority patent/CN101921236B/en
Priority to ES10010291T priority patent/ES2424881T3/en
Priority to MYPI20043301A priority patent/MY147449A/en
Priority to CA002533320A priority patent/CA2533320A1/en
Priority to SI200432067T priority patent/SI2287156T1/en
Priority to ES04764093T priority patent/ES2380206T3/en
Priority to NZ585188A priority patent/NZ585188A/en
Priority to MXPA06001759A priority patent/MXPA06001759A/en
Priority to US10/568,367 priority patent/US7893074B2/en
Priority to KR1020067003056A priority patent/KR100904570B1/en
Priority to RU2006107785/04A priority patent/RU2395500C2/en
Priority to DK10010291.2T priority patent/DK2287156T3/en
Priority to AU2004264382A priority patent/AU2004264382A1/en
Priority to CN2004800227255A priority patent/CN1832929B/en
Priority to PL04764093T priority patent/PL1660458T3/en
Priority to PT100102912T priority patent/PT2287156E/en
Priority to AT04764093T priority patent/ATE542801T1/en
Priority to PL10010291T priority patent/PL2287156T3/en
Priority to PT04764093T priority patent/PT1660458E/en
Priority to EP04764093A priority patent/EP1660458B1/en
Priority to PCT/EP2004/009099 priority patent/WO2005016894A1/en
Priority to EP10010291.2A priority patent/EP2287156B1/en
Priority to JP2006522998A priority patent/JP4607879B2/en
Priority to TW093124290A priority patent/TWI378923B/en
Priority to SG200806063-4A priority patent/SG145749A1/en
Priority to DK04764093.3T priority patent/DK1660458T3/en
Priority to BR122019017579A priority patent/BR122019017579B8/en
Priority to BRPI0413616A priority patent/BRPI0413616B8/en
Priority to SI200431849T priority patent/SI1660458T1/en
Priority to ARP040102945A priority patent/AR045458A1/en
Priority to IL170546A priority patent/IL170546A/en
Priority to TNP2005000225A priority patent/TNSN05225A1/en
Priority to EC2005006019A priority patent/ECSP056019A/en
Priority to MA28510A priority patent/MA27668A1/en
Priority to IS8062A priority patent/IS2961B/en
Priority to NO20054726A priority patent/NO331977B1/en
Priority to IL173129A priority patent/IL173129A0/en
Priority to ZA2006/00464A priority patent/ZA200600464B/en
Priority to TNP2006000052A priority patent/TNSN06052A1/en
Priority to EC2006006371A priority patent/ECSP066371A/en
Priority to MA28815A priority patent/MA27994A1/en
Priority to CO06016492A priority patent/CO5680434A2/en
Priority to IS8349A priority patent/IS2873B/en
Priority to NO20061214A priority patent/NO333306B1/en
Priority to HK11101680.0A priority patent/HK1147495A1/en
Priority to HK06112236.3A priority patent/HK1091813A1/en
Priority to AU2008229685A priority patent/AU2008229685B2/en
Priority to JP2010162177A priority patent/JP2010241830A/en
Priority to US12/984,519 priority patent/US20110098280A1/en
Priority to US13/095,760 priority patent/US8263590B2/en
Priority to CY20121100300T priority patent/CY1112571T1/en
Priority to HRP20120335TT priority patent/HRP20120335T1/en
Priority to CY20131100414T priority patent/CY1114238T1/en
Priority to HRP20130724TT priority patent/HRP20130724T1/en
Priority to CY20131100696T priority patent/CY1117015T1/en
Priority to ARP170100728A priority patent/AR107965A2/en
Priority to ARP190100267A priority patent/AR114354A2/en
Ceased legal-status Critical Current

Links

GB0319227A 2003-03-14 2003-08-15 Organic compounds Ceased GB0319227D0 (en)

Priority Applications (82)

Application Number Priority Date Filing Date Title
GBGB0305929.2A GB0305929D0 (en) 2003-03-14 2003-03-14 Organic compounds
GB0319227A GB0319227D0 (en) 2003-08-15 2003-08-15 Organic compounds
ES10009414T ES2409885T3 (en) 2003-03-14 2004-03-12 2,4-Di (phenylamino) pyrimidines useful for the treatment of neoplastic diseases and inflammatory and immune system disorders
EP10009414A EP2275413B1 (en) 2003-03-14 2004-03-12 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
BR122019010008A BR122019010008B8 (en) 2003-03-14 2004-03-12 pyrimidine derivatives, their use, and pharmaceutical composition and combination
AT04719989T ATE497495T1 (en) 2003-03-14 2004-03-12 2,4-DI(PHENYLAMINO)PYRIMIDINES SUITABLE FOR THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISEASES AND DISEASES OF THE IMMUNE SYSTEM
KR1020057017082A KR101148261B1 (en) 2003-03-14 2004-03-12 2,4-diphenylaminopyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
SI200432034T SI2275413T1 (en) 2003-03-14 2004-03-12 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
MXPA05009883A MXPA05009883A (en) 2003-03-14 2004-03-12 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders.
EP04719989A EP1606265B1 (en) 2003-03-14 2004-03-12 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
PL10009414T PL2275413T3 (en) 2003-03-14 2004-03-12 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
NZ542219A NZ542219A (en) 2003-03-14 2004-03-12 2,4-di(phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory diseases and immune system disorders
PCT/EP2004/002616 WO2004080980A1 (en) 2003-03-14 2004-03-12 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
PT04719989T PT1606265E (en) 2003-03-14 2004-03-12 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
CA2518932A CA2518932C (en) 2003-03-14 2004-03-12 2,4-di(phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
DK10009414.3T DK2275413T3 (en) 2003-03-14 2004-03-12 2,4-di (phenylamino) pyrimidines suitable for the treatment of neoplastic diseases, inflammatory and immune system disorders.
CN2004800130419A CN1788001B (en) 2003-03-14 2004-03-12 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
PL04719989T PL1606265T3 (en) 2003-03-14 2004-03-12 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
AU2004220338A AU2004220338B2 (en) 2003-03-14 2004-03-12 2, 4- DI (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
RU2005131721/04A RU2400477C2 (en) 2003-03-14 2004-03-12 2,4-di(phenylamino)pyrimidines, applied in treatment of neoplastic diseases, inflammatory disorders and immune system disorders
DE602004031287T DE602004031287D1 (en) 2003-03-14 2004-03-12 FOR THE TREATMENT OF 2,4-DI (PHENYLAMINO) PYRIMIDINES SUITABLE FOR NEOPLASTIC DISEASES, INFLAMMATORY DISEASES AND DISEASES OF THE IMMUNE SYSTEM
PT100094143T PT2275413E (en) 2003-03-14 2004-03-12 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
BRPI0408347A BRPI0408347B8 (en) 2003-03-14 2004-03-12 pyrimidine derivatives, their use, and pharmaceutical composition and combination
US10/549,250 US7964592B2 (en) 2003-03-14 2004-03-12 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
JP2006504673A JP4796487B2 (en) 2003-03-14 2004-03-12 2,4-Di (phenylamino) pyrimidine useful for the treatment of neoplastic diseases, inflammation and immune system disorders
CN2010102347117A CN101921236B (en) 2003-03-14 2004-03-12 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
ES10010291T ES2424881T3 (en) 2003-08-15 2004-08-13 2,4-Di (phenylamino) -pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
MYPI20043301A MY147449A (en) 2003-08-15 2004-08-13 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
CA002533320A CA2533320A1 (en) 2003-08-15 2004-08-13 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
SI200432067T SI2287156T1 (en) 2003-08-15 2004-08-13 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
ES04764093T ES2380206T3 (en) 2003-08-15 2004-08-13 2,4-Pyrimidinediamines useful for the treatment of neoplastic diseases, inflammatory and immune system disorders
NZ585188A NZ585188A (en) 2003-08-15 2004-08-13 2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
MXPA06001759A MXPA06001759A (en) 2003-08-15 2004-08-13 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders.
US10/568,367 US7893074B2 (en) 2003-08-15 2004-08-13 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
KR1020067003056A KR100904570B1 (en) 2003-08-15 2004-08-13 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
RU2006107785/04A RU2395500C2 (en) 2003-08-15 2004-08-13 2,4-pyrimidine diamines used in treating neoplastic diseases, inflammatory and immune disorders
DK10010291.2T DK2287156T3 (en) 2003-08-15 2004-08-13 2,4-Di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory disorders and disorders of the immune system
AU2004264382A AU2004264382A1 (en) 2003-08-15 2004-08-13 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
CN2004800227255A CN1832929B (en) 2003-08-15 2004-08-13 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
PL04764093T PL1660458T3 (en) 2003-08-15 2004-08-13 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
PT100102912T PT2287156E (en) 2003-08-15 2004-08-13 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
AT04764093T ATE542801T1 (en) 2003-08-15 2004-08-13 2,4-PYRIMIDIINDIAMINES SUITABLE FOR THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISEASES AND DISEASES OF THE IMMUNE SYSTEM
PL10010291T PL2287156T3 (en) 2003-08-15 2004-08-13 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
PT04764093T PT1660458E (en) 2003-08-15 2004-08-13 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
EP04764093A EP1660458B1 (en) 2003-08-15 2004-08-13 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
PCT/EP2004/009099 WO2005016894A1 (en) 2003-08-15 2004-08-13 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
EP10010291.2A EP2287156B1 (en) 2003-08-15 2004-08-13 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
JP2006522998A JP4607879B2 (en) 2003-08-15 2004-08-13 2,4-Pyrimidinediamine useful for the treatment of neoplastic diseases, inflammation and immune disorders
TW093124290A TWI378923B (en) 2003-08-15 2004-08-13 Pyrimidine derivatives
SG200806063-4A SG145749A1 (en) 2003-08-15 2004-08-13 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
DK04764093.3T DK1660458T3 (en) 2003-08-15 2004-08-13 2,4-Pyrimidine diamines useful in the treatment of neoplastic diseases, inflammatory disorders and disorders of the immune system.
BR122019017579A BR122019017579B8 (en) 2003-08-15 2004-08-13 2,4-pyrimidinediamines, their uses, combination and pharmaceutical composition
BRPI0413616A BRPI0413616B8 (en) 2003-08-15 2004-08-13 2,4-pyrimidinediamines, their uses, and pharmaceutical composition
SI200431849T SI1660458T1 (en) 2003-08-15 2004-08-13 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
ARP040102945A AR045458A1 (en) 2003-08-15 2004-08-17 PIRIMIDINE DERIVATIVES
IL170546A IL170546A (en) 2003-03-14 2005-08-29 2,4-di(phenylamino)pyrimidines, process for their production, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments for the treatment of neoplastic diseases and inflammatory and immune system disorders
TNP2005000225A TNSN05225A1 (en) 2003-03-14 2005-09-13 2,4-di(phenylamino) pyrimidines useful in the treatment of neoplastic diseases inflammatory and immune system disorders
EC2005006019A ECSP056019A (en) 2003-03-14 2005-09-14 2,4-DI (PHENYLAMINE) USEFUL PYRIMIDINS IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND THE IMMUNE SYSTEM
MA28510A MA27668A1 (en) 2003-03-14 2005-09-23 2,4-DI (PHENYLAMINO) PYRIMIDINES USED TO TREAT NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS
IS8062A IS2961B (en) 2003-03-14 2005-10-06 2,4-di (phenylamino) pyrimidine useful in the treatment of neoplastic, inflammatory and immune disorders
NO20054726A NO331977B1 (en) 2003-03-14 2005-10-13 2,4-di (phenylamino) pyrimidines, process for their preparation, use thereof, and pharmaceutical composition containing such a compound
IL173129A IL173129A0 (en) 2003-08-15 2006-01-12 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
ZA2006/00464A ZA200600464B (en) 2003-08-15 2006-01-17 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases,inflammatory and immune system disordes
TNP2006000052A TNSN06052A1 (en) 2003-08-15 2006-02-14 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
EC2006006371A ECSP066371A (en) 2003-08-15 2006-02-15 2,4-PYRIMIDINADIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, IMMUNE SYSTEM INFLAMMATORY AND INFLAMMATORY
MA28815A MA27994A1 (en) 2003-08-15 2006-02-17 2,4-PYRIMIDINE DIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNE SYSTEM DISORDERS
CO06016492A CO5680434A2 (en) 2003-08-15 2006-02-20 2,4-USEFUL PYRIMIDINADIAMINS IN THE TREATMENT OF NEOPLASTIC DISEASES, IMMUNE SYSTEM AND INFLAMMATORY DISORDERS
IS8349A IS2873B (en) 2003-08-15 2006-03-13 2,4-pyrimidinediamine useful in the treatment of neoplasms, inflammatory and immune disorders
NO20061214A NO333306B1 (en) 2003-08-15 2006-03-15 2,4-pyrimidinediamines, pharmaceutical composition and combination including such a compound and use of the compound
HK11101680.0A HK1147495A1 (en) 2003-03-14 2006-06-12 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
HK06112236.3A HK1091813A1 (en) 2003-08-15 2006-11-07 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
AU2008229685A AU2008229685B2 (en) 2003-08-15 2008-09-29 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
JP2010162177A JP2010241830A (en) 2003-08-15 2010-07-16 2,4-pyrimidinediamine useful in treatment of neoplastic disease, inflammatory and immune system disorder
US12/984,519 US20110098280A1 (en) 2003-08-15 2011-01-04 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
US13/095,760 US8263590B2 (en) 2003-03-14 2011-04-27 Pyrimidine derivatives
CY20121100300T CY1112571T1 (en) 2003-08-15 2012-03-22 2,4-Pyrimidinodiamine Useful in the Treatment of Neoplastic Diseases, Inflammatory Disorders and Disorders of the Immune System
HRP20120335TT HRP20120335T1 (en) 2003-08-15 2012-04-16 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
CY20131100414T CY1114238T1 (en) 2003-03-14 2013-05-27 2,4 - DI (FENYLAMINO) - Pyrimidines useful in the treatment of neoplastic disorders, inflammatory disorders and disorders
HRP20130724TT HRP20130724T1 (en) 2003-08-15 2013-08-01 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
CY20131100696T CY1117015T1 (en) 2003-08-15 2013-08-13 2,4-DI (FAINYLAMINO) - Pyrimidine Useful in the Treatment of Neoplastic Diseases, Inflammatory Disorders, and Immunosuppressants
ARP170100728A AR107965A2 (en) 2003-08-15 2017-03-23 PIRIMIDINE DERIVATIVES
ARP190100267A AR114354A2 (en) 2003-08-15 2019-02-04 PYRIMIDINE DERIVATIVES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0319227A GB0319227D0 (en) 2003-08-15 2003-08-15 Organic compounds

Publications (1)

Publication Number Publication Date
GB0319227D0 true GB0319227D0 (en) 2003-09-17

Family

ID=28052593

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0319227A Ceased GB0319227D0 (en) 2003-03-14 2003-08-15 Organic compounds

Country Status (3)

Country Link
CN (1) CN1832929B (en)
AR (2) AR107965A2 (en)
GB (1) GB0319227D0 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103641833A (en) * 2006-12-08 2014-03-19 Irm责任有限公司 Compounds and compositions as protein kinase inhibitors
WO2010132888A2 (en) * 2009-05-15 2010-11-18 Insight Genetics, Inc. Methods and compositions relating to fusions of alk for diagnosing and treating cancer
KR102156398B1 (en) * 2012-11-06 2020-09-15 상하이 포천 파마슈티컬 씨오 엘티디 Alk kinase inhibitors
KR102334260B1 (en) * 2013-03-14 2021-12-02 스미토모 다이니폰 파마 온콜로지, 인크. Jak2 and alk2 inhibitors and methods for their use
CN104628657A (en) * 2013-11-06 2015-05-20 韩冰 Class of compounds for treating ischemic brain damage and purpose thereof
CN104926824B (en) * 2014-03-17 2017-07-07 广东东阳光药业有限公司 Substituted heteroaryl compound and combinations thereof and purposes
CN106008503B (en) * 2015-03-31 2020-09-01 齐鲁制药有限公司 Spirocyclic aryl sulfones as protein kinase inhibitors
CN106146525B (en) * 2015-04-10 2018-11-02 山东轩竹医药科技有限公司 Three and ring class anaplastic lymphoma kinase inhibitor
CN106187915A (en) * 2015-05-27 2016-12-07 上海翰森生物医药科技有限公司 There is inhibitor of ALK Yu EGFR double activity and its preparation method and application
CN106349224A (en) * 2016-08-03 2017-01-25 山东大学 JAK kinase inhibitor with 4-amino-(1H)-pyrazole structure and preparation method and application thereof
CN110092759A (en) * 2018-01-31 2019-08-06 陆柯潮 The chloro- 2,4- pyrimidine derivatives of 5- as anti-tumor drug
CN114716385B (en) * 2022-04-08 2024-03-12 北京师范大学 Compound of targeted focal adhesion kinase, preparation method and application

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AR107965A2 (en) 2018-07-04
CN1832929B (en) 2012-11-07
AR114354A2 (en) 2020-08-26
CN1832929A (en) 2006-09-13

Similar Documents

Publication Publication Date Title
GB0301259D0 (en) Organic compounds
GB0303503D0 (en) Organic compounds
GB0306715D0 (en) Organic compounds
GB0307553D0 (en) Organic compounds
GB0307856D0 (en) Organic compounds
GB0319227D0 (en) Organic compounds
GB0302876D0 (en) Organic compounds
GB0307860D0 (en) Organic compounds
GB0300095D0 (en) Organic compounds
GB0301938D0 (en) Organic compounds
GB0301471D0 (en) Organic compounds
GB0302748D0 (en) Organic compounds
GB0303506D0 (en) Organic compounds
GB0306071D0 (en) Organic compounds
GB0306070D0 (en) Organic compounds
GB0307277D0 (en) Organic compounds
GB0302991D0 (en) Organic compounds
GB0307440D0 (en) Organic compounds
GB0305684D0 (en) Organic compounds
GB0301262D0 (en) Organic compounds
GB0303867D0 (en) Organic compounds
GB0303323D0 (en) Organic compounds
GB0303321D0 (en) Organic compounds
GB0303095D0 (en) Organic compounds
GB0304641D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)